References:
1. Stepan H, Galindo A, Hund M, Schlembach D, Sillman J, Surbek D, et
al. Clinical utility of sFlt-1 and PlGF in screening, prediction,
diagnosis and monitoring of pre-eclampsia and fetal growth restriction.
Ultrasound Obstet Gynecol. 2022.2. Bonacina E, Armengol-Alsina M,
Hurtado I, Garcia-Manau P, Ferrer-Oliveras R, Monreal S, et al. sFlt-1
to PlGF ratio cut-offs to predict adverse pregnancy outcomes in
early-onset FGR and SGA: a prospective observational study. J Obstet
Gynaecol. 2022:1-6.3. Benton SJ, McCowan LM, Heazell AE, Grynspan D,
Hutcheon JA, Senger C, et al. Placental growth factor as a marker of
fetal growth restriction caused by placental dysfunction. Placenta.
2016;42:1-8.4. Wang A, Holston AM, Yu KF, Zhang J, Toporsian M,
Karumanchi SA, et al. Circulating anti-angiogenic factors during
hypertensive pregnancy and increased risk of respiratory distress
syndrome in preterm neonates. J Matern Fetal Neonatal Med.
2012;25(8):1447-52.5. Kingdom J, Ashwal E, Lausman A, Liauw J, Soliman
N, Figueiro-Filho E, et al. Guideline No. 442: Fetal Growth Restriction:
Screening, Diagnosis, and Management in Singleton Pregnancies. Journal
of obstetrics and gynaecology Canada : JOGC = Journal d’obstetrique et
gynecologie du Canada : JOGC. 2023;45(10):102154.6. Andrikos A, Andrikos
D, Schmidt B, Birdir C, Kimmig R, Gellhaus A, et al. Course of the
sFlt-1/PlGF ratio in fetal growth restriction and correlation with
biometric measurements, feto-maternal Doppler parameters and time to
delivery. Archives of gynecology and obstetrics. 2022;305(3):597-605.7.
Shinar S, Tigert M, Agrawal S, Parks WA, Kingdom JC. Placental growth
factor as a diagnostic tool for placental mediated fetal growth
restriction. Pregnancy Hypertens. 2021;25:123-8.8. Gordijn SJ, Beune IM,
Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al. Consensus
definition of fetal growth restriction: a Delphi procedure. Ultrasound
Obstet Gynecol. 2016;48(3):333-9.9. Cote ML, Giguere Y, Forest JC,
Audibert F, Johnson JA, Okun N, et al. First-Trimester PLGF and PAPP-A
and the Risk of Placenta-Mediated Complications: PREDICTION Prospective
Study. Journal of obstetrics and gynaecology Canada : JOGC = Journal
d’obstetrique et gynecologie du Canada : JOGC. 2024:102732.10. Agrawal
S, Parks WT, Kingdom JC. Uterine and umbilical artery Doppler combined
with PlGF assay for placental function expertise in the assessment of
fetal growth restriction: a response. Am J Obstet Gynecol. 2022.11.
McLaughlin K, Snelgrove JW, Audette MC, Syed A, Hobson SR, Windrim RC,
et al. PlGF (Placental Growth Factor) Testing in Clinical Practice:
Evidence From a Canadian Tertiary Maternity Referral Center.
Hypertension. 2021;77(6):2057-65.12. Yanachkova V, Staynova R, Naseva E,
Kamenov Z. The Role of Placental Growth Factor in the Prediction of
Carbohydrate and Thyroid Disorders during Pregnancy. Medicina (Kaunas).
2022;58(2).13. McLaughlin K, Hobson SR, Chandran AR, Agrawal S, Windrim
RC, Parks WT, et al. Circulating maternal placental growth factor
responses to low-molecular-weight heparin in pregnant patients at risk
of placental dysfunction. Am J Obstet Gynecol.
2022;226(2S):S1145-S56.e1.14. Zhang J, Merialdi M, Platt LD, Kramer MS.
Defining normal and abnormal fetal growth: promises and challenges. Am J
Obstet Gynecol. 2010;202(6):522-8.15. Ahmed AM, Grandi SM, Pullenayegum
E, McDonald SD, Beltempo M, Premji SS, et al. Short-Term and Long-Term
Mortality Risk After Preterm Birth. JAMA Netw Open.
2024;7(11):e2445871.16. Agrawal S, Parks WT, Zeng HD, Ravichandran A,
Ashwal E, Windrim RC, et al. Diagnostic utility of serial circulating
placental growth factor levels and uterine artery Doppler waveforms in
diagnosing underlying placental diseases in pregnancies at high risk of
placental dysfunction. Am J Obstet Gynecol. 2022;227(4):618.e1-.e16.17.
Anderson N, De Laat M, Benton S, von Dadelszen P, McCowan L. Placental
growth factor as an indicator of fetal growth restriction in late-onset
small-for-gestational age pregnancies. The Australian & New Zealand
journal of obstetrics & gynaecology. 2019;59(1):89-95.18. Noordzij M,
Dekker FW, Zoccali C, Jager KJ. Sample size calculations. Nephron Clin
Pract. 2011;118(4):c319-23.19. Selvaratnam RJ, Wallace EM, Wolfe R,
Anderson PJ, Davey MA. Association Between Iatrogenic Delivery for
Suspected Fetal Growth Restriction and Childhood School Outcomes. JAMA.
2021;326(2):145-53.20. Rafique Z, Awan MW, Iqbal S, Usmani NN, Ahmad M,
Amjad M, et al. The Ability of Ultrasound Sonography (USG) to Detect
Intrauterine Growth Restriction (IUGR) in the Third Trimester of
Pregnancy With the Gold Standard of IUGR (Parameters by USG Hadlock) as
a Diagnostic Criterion. Cureus. 2021;13(12):e20523.21. Mecacci F, Romani
E, Clemenza S, Zullino S, Avagliano L, Petraglia F. Early Fetal Growth
Restriction with or Without Hypertensive Disorders: a Clinical Overview.
Reprod Sci. 2024;31(3):591-602.22. Dyck R, Klomp H, Tan LK, Turnell RW,
Boctor MA. A comparison of rates, risk factors, and outcomes of
gestational diabetes between aboriginal and non-aboriginal women in the
Saskatoon health district. Diabetes Care. 2002;25(3):487-93.23. Longtine
MS, Nelson DM. Placental dysfunction and fetal programming: the
importance of placental size, shape, histopathology, and molecular
composition. Semin Reprod Med. 2011;29(3):187-96.24. Sibley CP, Turner
MA, Cetin I, Ayuk P, Boyd CA, D’Souza SW, et al. Placental phenotypes of
intrauterine growth. Pediatr Res. 2005;58(5):827-32.25. . !!! INVALID
CITATION !!! 21.26. Melamed N, Baschat A, Yinon Y, Athanasiadis A,
Mecacci F, Figueras F, et al. FIGO (international Federation of
Gynecology and obstetrics) initiative on fetal growth: best practice
advice for screening, diagnosis, and management of fetal growth
restriction. International journal of gynaecology and obstetrics: the
official organ of the International Federation of Gynaecology and
Obstetrics. 2021;152 Suppl 1(Suppl 1):3-57.27. Groom KM, McCowan LM,
Mackay LK, Lee AC, Said JM, Kane SC, et al. Enoxaparin for the
prevention of preeclampsia and intrauterine growth restriction in women
with a history: a randomized trial. Am J Obstet Gynecol. 2017;216(3):296
e1- e14.28. Sibiude J, Guibourdenche J, Dionne MD, Le Ray C, Anselem O,
Serreau R, et al. Placental growth factor for the prediction of adverse
outcomes in patients with suspected preeclampsia or intrauterine growth
restriction. PLoS One. 2012;7(11):e50208.29. Snowden JM, Klebanoff MA.
Accurate identification of cohort study designs in perinatal research: a
practical guide. Am J Obstet Gynecol. 2022;227(2):231-5 e1.30.
McLaughlin K, Nadeem L, Wat J, Baczyk D, Lye SJ, Kingdom JC. Low
molecular weight heparin promotes transcription and release of placental
growth factor from endothelial cells. American journal of physiology
Heart and circulatory physiology. 2020;318(4):H1008-H17.31. McLaughlin
K, Baczyk D, Potts A, Hladunewich M, Parker JD, Kingdom JC. Low
Molecular Weight Heparin Improves Endothelial Function in Pregnant Women
at High Risk of Preeclampsia. Hypertension. 2017;69(1):180-8.32. McVicar
JA, Orser BA, Wilson CR. No community left behind: advancing rural
anesthesia, surgery, and obstetric care in Canada. Can J Anaesth.
2022;69(12):1443-8.33. Lafond G, Haver CRA, Mcleod V, Clarke S,
Horsburgh B, Mcleod KM. Characteristics and residence of First Nations
patients and their use of health care services in Saskatchewan, Canada:
informing First Nations and Métis health services. Journal of Evaluation
in Clinical Practice. 2017;23(2):294-300.